Search Results
Your search for it matches 16118 pages
Showing 5301 - 5350Advanced HER2-Positive Breast Cancer: All Eyes on These Novel Agents
New agents for the treatment of advanced HER2-positive breast cancer should be coming soon to your clinic, according to Sara A. Hurvitz, MD, Director of the Breast Cancer Clinical Research Program and Associate Professor of Medicine at the David Geffen School of Medicine at the University of...
Updates From Additional Clinical Trials in HER2-Positive Breast Cancer
Here we present summaries of several additional clinical trials in HER2-positive breast cancer reported over the past year. Jame Abraham, MD, Chair of the Division of Hematology and Oncology at the Taussig Cancer Center, Cleveland Clinic, shared his perspective on several of these trials presented ...
Expert Point of View: Ian E. Krop, MD, PhD, Angela M. DeMichele, MD, MSCE, and Carlos L. Arteaga, MD
Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, Boston, said that margetuximab is one of three new “exciting” drugs in the HER2-positive setting with different mechanisms of action; the other two are tucatinib and trastuzumab deruxtecan. “Margetuximab is a modified version of trastuzumab...
Phase III SOPHIA Trial Evaluates Margetuximab/Chemotherapy vs Trastuzumab/Chemotherapy for HER2-Positive Breast Cancer
The second interim analysis of the phase III SOPHIA trial demonstrated a significant, though modest, improvement in progression-free survival, response rate, and clinical benefit with the addition of margetuximab to chemotherapy vs trastuzumab plus chemotherapy in patients with HER2-positive...
Neratinib in Previously TreatedHER2-Positive Metastatic Breast Cancer: Point of View From the NALA Trial
Neratinib is an oral pan-HER tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration (FDA) for two indications. The first is as adjuvant treatment of early-stage HER2-positive breast cancer following adjuvant trastuzumab therapy. The second is in combination with...
2020 Nobel Prize in Physiology or Medicine Awarded to Team Who Discovered Hepatitis C Virus
This year’s Nobel Prize in Physiology or Medicine was awarded to three scientists who have made a decisive contribution to the fight against blood-borne hepatitis, a major global health problem that causes cirrhosis and liver cancer in people around the world. Harvey J. Alter, MD; Michael Houghton, ...
Expert Point of View: Lisa A. Carey, MD
Invited study discussant Lisa A. Carey, MD, the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research and Deputy Director of Clinical Sciences at the University of North Carolina-Chapel Hill, framed her remarks as a tale of two trials. Dr. Carey asked these...
IMpassion131: No Benefit for Atezolizumab Plus Paclitaxel in Triple-Negative Breast Cancer
Based on some unexpected negative results, oncologists using atezolizumab for metastatic triple-negative breast cancer should pair it with nab-paclitaxel, not paclitaxel. In contrast to the overall survival benefit shown for atezolizumab plus nab-paclitaxel in the previous IMpassion130...
FDA Pipeline: Priority Review for Agents in Multiple Myeloma, Anaplastic Large Cell Lymphoma
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to therapies for pretreated patients with multiple myeloma and pediatric patients with ALK-positive anaplastic large cell lymphoma; granted Fast Track designation to novel agents in gastric/gastroesophageal junction...
Long-Term Outcomes With Neoadjuvant Therapy Followed by Surgery in Rectal Adenocarcinoma: Focus on Pathologic Response
For patients with rectal adenocarcinoma treated with neoadjuvant therapy followed by operative resection, “achieving a pathologic complete response is associated with excellent long-term disease-free and overall survival,” according to the results of a study reported by Naomi M. Sell, MD, MHS, of...
ASCO’s National Cancer Opinion Survey Reveals Concerns Over Delays in Cancer Screenings Due to COVID-19 and Inequities in Health Care
Findings from ASCO’s fourth annual National Cancer Opinion Survey showed the toll the COVID-19 pandemic is taking on patients with cancer and the concerns over delays in scheduling cancer screenings. In addition, a majority of survey respondents acknowledged that racism can impact the care a person ...
Is Cancer Mortality Higher in Counties That Experience Persistent Poverty?
Residents of counties that experience persistent poverty face a disproportionately high risk of cancer mortality, according to a study published by Jennifer L. Moss, PhD, and colleagues in Cancer Epidemiology, Biomarkers & Prevention. Persistent Poverty Areas of persistent poverty are defined...
Ending Systemic Racism in Oncology Is Everyone’s Responsibility
Five years ago, as Rachel B. Issaka, MD, MAS, was beginning her second year as a gastroenterology fellow and feeling proud of the progress she was making in her training, she was suddenly confronted with an all-too-familiar slight that underrepresented minority providers may often experience. As...
Genetic Testing May Be Cost-Effective for Newly Diagnosed Patients With GIST
In a paper published by Banerjee et al in JAMA Network Open, researchers reported that genetic testing is cost-effective and beneficial for newly diagnosed patients with metastatic gastrointestinal stromal tumors (GIST), a type of soft-tissue sarcoma that develops in specialized nerve cells in the...
An MSK Hospitalist Looks at Oncologists’ Attitudes About Inpatient Cancer Care
Each year in the United States, about five million adults with cancer are admitted to hospitals. Given our aging population, this trend will increase, putting added stress on the oncology community, which is already dealing with an impending workforce shortage. Although physician extenders, such...
Monika K. Krzyzanowska, MD, MPH, on Early-Stage Breast Cancer: Ambulatory Toxicity Management in the AToM Study
Monika K. Krzyzanowska, MD, MPH, of the Princess Margaret University Health Network, discusses study findings on remote proactive telephone-based toxicity management for patients with breast cancer receiving chemotherapy. Although the telehealth program was associated with fewer grade 3 toxicities...
Leukemia & Lymphoma Society Launches First Clinical Trial in Patients With Hematologic Malignancy and COVID-19
In response to studies showing that between 30% and 60% of patients with blood cancer are at risk of death if infected with COVID-19 compared with patients who are cancer-free, the Leukemia & Lymphoma Society (LLS) has announced its launch of the first clinical trial dedicated solely to this...
Recognizing the Coexistence of Symptoms of Pancreatic Cancer
Incidence rates for pancreatic cancer were 6-fold to 10-fold higher among participants in a study who had recent-onset diabetes and weight loss.1 This led the study authors to write: “The coexistence of these symptoms should be recognized by clinicians given that both the relative and absolute...
Greater Coverage, Patient Education, and Research for Telemedicine Needed During the COVID-19 Pandemic and Beyond
Flexibilities in reimbursement that have allowed the expanded use of telemedicine during the COVID-19 pandemic should continue and be made available to more providers and patients, according to a recent statement from ASCO. ASCO Interim Position Statement: Telemedicine in Cancer Care also calls for ...
Study Finds Recent-Onset Diabetes With Unintentional Weight Loss Linked to Increased Risk of Pancreatic Cancer
A large cohort study with close to 160,000 men and women reported that “recent-onset diabetes accompanied by weight loss was associated with a substantial increase in risk for pancreatic cancer and may represent a high-risk group in the general population for whom early detection strategies would...
Conquer Cancer Collaborates With Israel Cancer Research Fund for Career Development Award in Israel
Conquer Cancer®, the ASCO Foundation has joined forces with the Israel Cancer Research Fund (ICRF) to grant a 2020 Career Development Award (CDA) to a physician-scientist in Israel. The CDA supports early-career clinical and translational investigators during their first few years of faculty...
Cancer in My Community: Caring for Children With Cancer in Armenia
Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how providers work to care for people with cancer in their region. Why I Care for People With Cancer When you tell someone that you are a pediatric oncologist and treat children with cancer, the first...
COVID-19 Pandemic Delays Cancer Care and Strains Resources
Delays and cancellation of cancer treatments and other safety measures undertaken to minimize the risk of exposure to COVID-19 have generated a huge backlog in oncology care and research. The threat of delayed diagnoses looms while oncology professionals face burnout, according to new studies...
National Survey Shows Decline in Overall Youth E-Cigarette Use, Uptick in Use of Disposable Products
In september, 2020, the U.S. Food and Drug Administration (FDA), in partnership with the Centers for Disease Control and Prevention, released new data from the 2020 National Youth Tobacco Survey (NYTS). The results, published by Wang et al in Morbidity and Mortality Weekly Report (MMWR), showed 1.8 ...
Many Reasons to ‘Geriatricize’ Your Oncology Practice: Research Updates From ASCO20
“Older adults form the majority of patients with cancer.” For more than 3 decades now, almost every article, presentation, or discussion related to cancer and aging started with this statement. As I entered the field of geriatric oncology, I thought that by simply stating this fact, everyone would...
New Breast Cancer Agents and Concurrent Radiation: Risk or Benefit?
Most of the newer systemic treatments for breast cancer can be safely and effectively paired with radiation therapy—although there are some exceptions, according to Mylin A. Torres, MD, the Louisa and Rand Glenn Family Chair in Breast Cancer Research and Associate Professor of Radiation Oncology at ...
Neratinib in Previously Treated HER2-Positive Metastatic Breast Cancer: Point of View From the NALA Trial
Neratinib is an oral pan-HER tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration (FDA) for two indications. The first is as adjuvant treatment of early-stage HER2-positive breast cancer following adjuvant trastuzumab therapy. The second is in combination with...
I’ve Turned My Pain Into a New Life Purpose
The first half of 2016 was arguably the most exciting of my life. My wife, Jaione, and I had decided to leave the United Kingdom and move with our two children, Andrew, then 14, and Alba, then 10, to Denver, where I was taking on a leadership role in corporate affairs for a brewery company. By the...
Never Say Never
She was elderly, slightly confused, and very, very worried. I was not quite sure why. It was a minor procedure—a routine angiogram, one of a dozen to be performed that morning. The risks were so small that the job of admitting her had been handed to me, then a final-year medical student, with a...
With the Goal of Curing Cancer, Ezra M. Greenspan, MD, Helped Usher in the Modern Era of Chemotherapy
Born in Brooklyn on April 4, 1919, Ezra M. Greenspan, MD, did not stray far from his birthplace, spending most of his 5-decade medical career in New York. After graduating from New York University School of Medicine in 1942, he was accepted into the house training program at Mount Sinai Hospital...
Eric P. Winer, MD, Recipient of Lifetime Achievement in Mentoring Award
In September 2020, Eric P. Winer, MD, was honored with the William Silen Lifetime Achievement in Mentoring Award, presented by the Office for Diversity, Inclusion & Community Partnership at Harvard Medical School. Dr. Winer is Professor of Medicine, Harvard Medical School, and Director of the...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Botswana
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Botswana. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Early Cancer Experience Plants the Seed for a Career in Oncology to Grow for Joyce F. Liu, MD, MPH
As a young girl growing up in central New Jersey, Joyce F. Liu, MD, MPH, a medical oncologist specializing in gynecologic cancers at Dana-Farber Cancer Institute, Boston, dreamed of becoming an astronaut. However, she realized her fear of heights and propensity for motion sickness didn’t jive with...
IU Cancer Center Researcher Awarded $5.7 Million to Study Chemotherapy-Induced Hearing Loss, Toxicities
A researcher at the Indiana University (IU) Melvin and Bren Simon Comprehensive Cancer Center has been awarded a 5-year, $5.7 million National Cancer Institute (NCI) grant to evaluate long-term health outcomes for patients with cancer who receive platinum-based chemotherapies. An internationally...
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma
On July 24, 2020, brexucabtagene autoleucel, a CD19-directed genetically modified autologous T-cell immunotherapy, was granted accelerated approval for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.1,2 Brexucabtagene autoleucel is approved with a Risk Evaluation...
Updates on BCMA-Directed CAR-Modified T-Cell Gene Therapies
Outcomes in patients with triple-class–failure relapsed and refractory multiple myeloma who experience disease progression on immunomodulatory agents, proteasome inhibitors, and CD38 antibodies are dismal. Most recently, early results of three anti-B-cell maturation antigen (BCMA) chimeric antigen...
Sentinel Lymph Node Biopsy and Age-Related Mutations: Therapeutic and Predictive Implications in Melanoma
Findings from a study among patients with melanoma randomly assigned to observation following removal of a positive sentinel lymph node “strongly support the therapeutic effect of the sentinel lymph node biopsy in providing long-term regional nodal disease control in the large majority of...
Age at Diagnosis May Improve Risk Stratification for Patients With Breast Cancer
Age is not just a number when it comes to prognosis for invasive breast cancer. According to data presented during the 2020 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care, age at diagnosis of breast cancer is a highly prognostic clinical variable that warrants...
Expert Point of View: Christopher Anker, MD
Christopher Anker, MD, a radiation oncologist at The University of Vermont Medical Center and Associate Professor at the Larner College of Medicine at the University of Vermont, Burlington, told The ASCO Post that although the benefit to overall survival disappeared with time likely due to a power ...
Neoadjuvant Chemotherapy Alone vs Chemoradiation in Esophageal Cancer: No Difference Found in Long-Term Survival
Improved local-regional tumor control may not be enough to justify the increased morbidity of adding neoadjuvant radiation to chemotherapy in esophageal and gastroesophageal junction cancers, according to a pair of studies presented during the 2020 Society of Surgical Oncology (SSO) International...
Expert Point of View: George J. Chang, MD, MS, FACS, FASCRS
George J. Chang, MD, MS, FACS, FASCRS, of the Department of Surgical Oncology at The University of MD Anderson Cancer Center, told The ASCO Post that although adjuvant therapy in stage II disease has been shown to improve outcomes in patients with certain high-risk features, “the benefits are...
Corticosteroids Improve Survival in Critically Ill Patients With COVID-19, According to International Trial
In a demonstration of global collaboration, clinician-scientists have pooled data from 121 hospitals in 8 countries to find that inexpensive, widely available steroids may improve the odds that very sick patients with COVID-19 will survive the illness. The findings were made through the Randomized...
Azacitidine Tablets for Continued Treatment in Acute Myeloid Leukemia
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 1, 2020, azacitidine tabletswere approved...
Expert Point of View: David Scott, MBChB, PhD
“In 2015, papers showed that ctDNA could suggest relapse noninvasively in serial plasma samples. In those studies, ctDNA was positive prior to relapse detected by computed tomography scans,” explained session moderator David Scott, MBChB, PhD, of the Center for Lymphoid Cancer, BC Cancer,...
Applications of Circulating Tumor DNA Liquid Biopsy Continue to Expand in Lymphomas
Liquid biopsies using circulating tumor DNA (ctDNA) have the potential to personalize medicine for patients with lymphoma, going beyond traditional markers and risk factors to provide dynamic assessments over time. Expanded applications of ctDNA liquid biopsy beyond diagnosis include early response ...
The New Face of Medical Visits
“Good morning! I’m Dr. Saksena. It’s a pleasure to meet you.” I wave my introduction as I enter the room. Two women sit beside each other. One of them wears a mask that reads “lipstick optional,” and the other dons a surgical mask. This is a new visit for breast cancer, but I haven’t yet deciphered ...
Efforts to Broaden Eligibility Criteria for Clinical Trials Seek to Include More Racial and Ethnic Minority Patients
A review of the 2019 Drug Trials Snapshots Report1 from the U.S. Food and Drug Administration (FDA) showed that although female participation in clinical trials grew to 72% from 56% in the FDA’s 2018 Drug Trials Snapshots Report,2 ethnic minority participation in clinical trials actually declined...
Elderly Patients With Advanced Colorectal Cancer Treated With Adjuvant Oxaliplatin Plus Fluoropyrimidines: Tolerability and Benefit
Among patients with stage III colon cancer, patients aged 70 or older were less tolerant of adjuvant oxaliplatin/flouropyrimidine therapy, in addition to having poorer relapse-free interval rates on the regimen, according to findings from a large subgroup analysis of the phase III TOSCA trial...
AACR Releases 10th Edition of Annual Cancer Progress Report
The American Association for Cancer Research (AACR) has released the 10th edition of its annual Cancer Progress Report. The report highlights how cancer research, largely supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI), is...
